Media Articles Related to Navelbine (Vinorelbine)
Novel biomarker identified for head and neck cancer, non-small cell lung cancer
Source: Ear, Nose and Throat News From Medical News Today [2014.04.05]
A new biomarker linked to better outcomes for patients with head and neck cancers and non-small cell lung cancer has been identified by a team led by a scientist from the Florida campus of The...
Team identifies novel biomarker for head and neck cancer and non-small cell lung cancer
Source: Biology / Biochemistry News From Medical News Today [2014.04.04]
A team led by a scientist from the Florida campus of The Scripps Research Institute (TSRI) has identified a new biomarker linked to better outcomes of patients with head and neck cancers and...
NSCLC Patients Without EGFR Mutations Better on Chemo
Source: Medscape Hematology-Oncology Headlines [2014.04.09]
Chemotherapy may be preferable to targeted agents in patients with non-small cell lung cancer without EGFR mutations, suggests a new meta-analysis.
Medscape Medical News
Comparison of treatments for advanced lung cancer shows chemotherapy may be best for certain patients
Source: Lung Cancer News From Medical News Today [2014.04.09]
Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor...
Mixed Results in NSCLC, SCLC Trials (CME/CE)
Source: MedPage Today Pulmonology [2014.04.01]
(MedPage Today) -- Two-thirds of patients with recurrent, mutated non-small cell lung cancer responded to an investigational agent that selectively targets mutant cells and spares normal ones, results of a preliminary trial showed.
Published Studies Related to Navelbine (Vinorelbine)
Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study. [2011.05]
BACKGROUND/PURPOSE: This study compared front-line treatment with docetaxel or vinorelbine in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC)... CONCLUSIONS: Docetaxel has an efficacy comparable to that of vinorelbine as first-line treatment in elderly patients with NSCLC and has an acceptable toxicity profile. The trial was closed prematurely because of low accrual, thus limiting the strength of the conclusions derived. Copyright (c) 2011. Published by Elsevier Inc.
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. [2011.04.12]
BACKGROUND: To evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naive relapsed breast cancer patients... CONCLUSIONS: Both anthracycline- containing regimens evaluated in the present study seem to be active and with a satisfactory tolerability in anthracycline-naive relapsed breast cancer patients.
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). [2011.04]
BACKGROUND: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer... CONCLUSION: Although response rate, PFS and survival were non-different in both groups, toxicity was significantly worse in group B and therefore further investigation of P-Vin is of no value. (c) The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. [2011.03.29]
BACKGROUND: An increasing proportion of patients are exposed to anthracyclines and/or taxanes in the adjuvant or neoadjuvant setting. Re-exposure in the metastatic stage is limited by drug resistance, thus evaluation of non-cross-resistant regimens is mandatory... CONCLUSIONS: This randomised phase II trial has revealed comparable results for three gemcitabine-based regimens regarding treatment efficacy and toxicity. Gemcitabine-based chemotherapy appears to be a worthwhile treatment option for pretreated patients with metastatic breast cancer.
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. [2011.03]
PURPOSE: This study evaluates the activity and toxicity of the paclitaxel/carboplatin (PC) doublet versus vinorelbine/carboplatin (VC) doublet as second-line treatment in patients who have advanced non-small-cell lung cancer (NSCLC)... CONCLUSIONS: Platinum-based doublets with either paclitaxel or vinorelbine in patients with advanced/metastatic NSCLC pretreated with front-line docetaxel/gemcitabine show comparable efficacy when used in the second-line setting. Copyright (c) 2011. Published by Elsevier Inc.
Clinical Trials Related to Navelbine (Vinorelbine)
Vinorelbine/Gemcitabine Verses Vinorelbine/Carboplatin in Advanced Non-Small Cell Lung Cancer [Recruiting]
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer [Active, not recruiting]
The purpose of this study is to find the highest dose of capecitabine and oral navelbine that
can be given without causing severe side effects, and to determine the safety, tolerability,
and effects (good and bad) of capecitabine given with oral navelbine to patients with
advanced breast cancer.
Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer [Recruiting]
The purpose of this study is to define the schedule and dose of oral vinorelbine (Navelbine)
to be used with erlotinib in non-small cell lung cancer.
BIBW 2992 and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2 [Recruiting]
To identify the MTD of BIBW 2992 therapy in combination with vinorelbine i. v. and oral
Safety and anti-tumour efficacy data and determination of pharmacokinetic characteristics of
BIBW 2992, vinorelbine i. v. and vinorelbine oral.
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer [Completed]
The purpose of this study is it to determine how well patients with non-small cell lung
cancer respond to cetuximab plus vinorelbine. We would also like to determine the safety of
cetuximab plus vinorelbine in people 70 years of age or older with advanced non-small cell
Reports of Suspected Navelbine (Vinorelbine) Side Effects
Febrile Neutropenia (10),
Confusional State (8),
Tongue Neoplasm Malignant Stage Unspecified (8),
Neoplasm Progression (6),
Pleural Effusion (6),
Neutropenia (6), more >>